代谢性酸中毒与CKD进展:当前指南与考量
该文评述KDIGO关于CKD代谢性酸中毒的实践要点,指出其基于安慰剂对照RCT提出血清碳酸氢盐<18 mmol/L的干预切点,可能导致大量患者未治疗而影响CKD进展。作者通过批判性评估认为所引证据可作不同解读,建议修订实践要点并提出了研究议程。
要点
- KDIGO实践要点建议血清碳酸氢盐<18 mmol/L时考虑治疗,但非推荐。
- 该切点可能使大量CKD代谢性酸中毒患者未获治疗,影响CKD进展。
- 作者认为所引证据可作不同解读,建议修订实践要点。
核心结论
- KDIGO实践要点基于安慰剂对照RCT提出血清碳酸氢盐<18 mmol/L的干预切点,但可能导致大量CKD患者未治疗。
- 作者批判性评估认为所引证据可作不同解读,建议修订实践要点并制定研究议程。
研究设计与样本
- 指南评述:针对KDIGO关于CKD代谢性酸中毒的实践要点进行批判性评估。
主要发现
- KDIGO实践要点建议考虑治疗以预防代谢性酸中毒, proposed cutoff为血清碳酸氢盐<18 mmol/L。
- 该切点可能使大量CKD患者未治疗,影响CKD进展及健康结局。
- 指南未纳入所有可用证据。
关键数值与推荐
- KDIGO实践要点:考虑治疗以预防代谢性酸中毒,血清碳酸氢盐<18 mmol/L为 proposed cutoff。
临床怎么用
- 临床管理CKD代谢性酸中毒时需注意KDIGO实践要点的局限性,个体化评估治疗。
局限性
- KDIGO指南未纳入所有可用证据,且实践要点非推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Observational evidence suggests that metabolic acidosis in chronic kidney disease (CKD) is a driver of CKD progression, but there remains significant debate regarding the quantity and quality of published evidence to support treatment. The Kidney Disease: Improving Global Outcomes (KDIGO) guidance on metabolic acidosis in CKD highlighted this controversy by publishing practice points, not recommendations, based primarily on placebo-controlled randomized controlled trials. These practice points suggest considering treatment to prevent metabolic acidosis with a proposed cutoff for serum bicarbonate < 18 mmol/L. However, this approach means a substantial number of individuals with CKD may now remain untreated for their metabolic acidosis, which may impact CKD progression with associated adverse health outcomes. Additionally, the guidance does not include all the available evidence. From our critical appraisal we suggest that the evidence cited could have been interpreted differently. We recommend that the practice points published are revised based on critical appraisal of the cited evidence to inform the clinical management of individuals with metabolic acidosis in CKD. We also suggest a research agenda for future studies to help resolve this issue.
引用
- Beynon-Cobb B, Visser W, Hoorn EJ, et al. Metabolic Acidosis and Progression of CKD: Current Guidelines and Considerations. Am J Kidney Dis. 2026. PMID: 42349771. doi:10.1053/j.ajkd.2026.03.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。